Federal Register / Vol. 86, No. 31 / Thursday, February 18, 2021 / Notices 10081 

EARLY TERMINATIONS GRANTED—Continued 

[12/01/2020 12:00:00 a.m.,12/31/2020 12:00:00 a.m.] 

12/28/2020 

20210205 ...... G Caesars Entertainment, Inc.; William Hill PLC; Caesars Entertainment, Inc. 

20210689 ...... G Biogen Inc.; Sage Therapeutics, Inc; Biogen Inc. 

20210690 ...... G Thoma Bravo Fund XIII–A, L.P.; Venafi, Inc; Thoma Bravo Fund XIII–A, L.P. 

20210691 ...... G Nasdaq, Inc.; Verafin Holdings, Inc.; Nasdaq. Inc. 

12/31/2020 

20210651 ...... G Stephen Griggs; AdaptHealth Corp.; Stephen Griggs. 

20210652 ...... G SkyKnight Aero Holdings, LLC; AdaptHealth Corp.; SkyKnight Aero Holdings, LLC. 

20210653 ...... G Peloton Equity AeroCare SPV I, L.P.; AdaptHealth Corp.; Peloton Equity AeroCare SPV I, L.P. 

FOR FURTHER INFORMATION CONTACT: 

Theresa Kingsberry (202–326–3100), 

Program Support Specialist, Federal 

Trade Commission Premerger 

Notification Office, Bureau of 

Competition, Room CC–5301, 

Washington, DC 20024. 

By direction of the Commission. 

April J. Tabor, 

Secretary. 

[FR Doc. 2021–03183 Filed 2–17–21; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP)—Funding 

Opportunity Announcement (FOA), 

RFA OH–21–003, Extension of the 

World Trade Center Health Registry 

(U50); Amended Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the Disease, Disability, 

and Injury Prevention and Control 

Special Emphasis Panel (SEP)—Funding 

Opportunity Announcement (FOA), 

RFA OH–21–003, Extension of the 

World Trade Center Health Registry 

(U50), April 13, 2021; 9:00 a.m.–6:00 

p.m., EDT in the original FRN. 

The virtual meeting was published in 

the Federal Register on Monday, 

January 11, 2021, Volume 86, Number 6, 

page 1976. 

The meeting on April 13, 2021 is 

being amended to change the time and 

should read as follows: 

Time: 1:00 p.m.–3:00 p.m., EDT. 

The meeting is closed to the public. 

FOR FURTHER INFORMATION CONTACT: 

Marilyn Ridenour B.S.N., M.B.A., 

M.P.H., C.P.H., C.I.C., CAPT, USPHS, 

Scientific Review Officer, CDC, National 

Institute for Occupational Safety and 

Health, 1095 Willowdale Road, Mailstop 

1811, Morgantown, West Virginia 

26505, Telephone (304) 285–5879. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2021–03231 Filed 2–17–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Advancing 

Translational Sciences; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Advancing Translational Sciences Special 

Emphasis Panel; CTSA Revision Award. 

Date: March 9, 2021. 

Time: 12:00 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Center for Advancing 

Translational Sciences, National Institutes of 

Health, 6701 Democracy Boulevard, Room 

1078, Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Rahat (Rani) Khan, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review, National Center for Advancing 

Translational Sciences, National Institutes of 

Health, 6701 Democracy Boulevard, Room 

1078, Bethesda, MD 20892, 301–894–7319 

khanr2@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.350, B—Cooperative 

Agreements; 93.859, Biomedical Research 

and Research Training, National Institutes of 

Health, HHS) 

Dated: February 11, 2021. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–03190 Filed 2–17–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: Autologous Therapy 

for the Treatment of Autoimmune 

Disease Using Chimeric Antigen 

Receptors Targeting CD19 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Cancer Institute, 

an institute of the National Institutes of 

Health, Department of Health and 

Human Services, is contemplating the 

grant of an Exclusive Patent License to 

practice the inventions embodied in the 

Patents and Patent Applications listed 

in the Supplementary Information 

section of this notice to Kyverna 

Therapeutics (‘‘Kyverna’’) located in 

Berkeley, CA. 


jbell on DSKJLSW7X2PROD with NOTICES